What's Happening?
Corrixr Therapeutics, a pre-clinical genetic medicine company, has appointed Hilary M. Malone, Ph.D., as its new Chief Executive Officer. Dr. Malone brings over 25 years of experience in drug development and biotech leadership, having previously held
senior roles at major pharmaceutical companies and biotech startups. Her appointment comes as Corrixr advances its lead program, CXR101, targeting squamous cell carcinomas, toward IND filing and first-in-human trials. Dr. Malone succeeds Eric B. Kmiec, Ph.D., who will continue as Chief Scientific Officer.
Why It's Important?
Dr. Malone's appointment is a strategic move for Corrixr as it seeks to transition from pre-clinical to clinical stages in its development of CXR101. Her extensive experience in regulatory affairs and clinical development is expected to accelerate the company's progress in bringing innovative cancer treatments to market. This leadership change is significant for stakeholders, including investors and patients, as it signals a commitment to advancing potentially transformative therapies for cancers with limited treatment options.
What's Next?
Under Dr. Malone's leadership, Corrixr will focus on advancing CXR101 through the necessary regulatory and clinical milestones. The company aims to initiate first-in-human trials, which will be a critical step in demonstrating the treatment's efficacy and safety. Success in these trials could lead to further investment and partnerships, positioning Corrixr as a leader in genetic medicine for cancer treatment. The biotech community will be watching closely to see how Dr. Malone's strategies impact the company's trajectory.
